OPCML is frequently silenced by promoter methylation rather than genetic deletion in NPC, as well as multiple other carcinomas and lymphomas.
A recent report demonstrated ICSBP downregulation in non-hematopoietic tumors, including nasopharyngeal, esophageal, and multiple other carcinomas, suggesting that ICSBP may function as a tumor suppressor in various tumors.
It has been shown that HIF-2α promotes cell-cycle progression in hypoxic renal cell carcinoma (RCC) and multiple other cell lines.
In contrast, we found no evidence for methylation of P3H2 in analysis of cell lines from multiple other tumour types, including ovarian and renal adenocarcinomas, squamous carcinomas of the vulva and head and neck, malignant melanoma and glioma.
Briefly, breast, prostate, renal cell, and thyroid carcinoma, multiple myeloma, and malignant lymphoma were included in Group 3; sarcomas and other carcinomas were included in Group 2; and lung, gastric, and hepatocellular carcinoma and melanoma were included in Group 1.
For example, lung, gastric, and hepatocellular carcinoma and melanoma were assigned to Group 1; sarcomas and other carcinomas, Group 2; and breast, prostate, renal cell, and thyroid carcinoma, multiple myeloma, and malignant lymphoma, Group 3. The definitions used for this study were similar to those previously described [ 15].
These regions contain clusters of tumor suppressor genes involved in multiple cancer types such as lung, kidney, breast, cervical, head and neck, nasopharyngeal, prostate and other carcinomas.
We then examined its epigenetic inactivation in NPC and multiple other tumors which have not been studied for this gene, including esophageal, lung, gastric, hepatocellular, colorectal, breast, cervical and prostate carcinomas, as well as non-Hodgkin and Hodgkin lymphomas.
Bleomycin indications were: head-and-neck squamous cell carcinomas (11), Hodgkin's lymphoma (2), other carcinomas (2).
c-MET phosphorylation has been reported in Non-Small Cell Lung NSCLCcarcinomaoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and other carcinomas [7] [9].
Briefly, breast, prostate, renal cell, and thyroid carcinomas, multiple myeloma, and malignant lymphoma, which are diagnoses associated with the longest median survival time, were included in Group 3; sarcomas and other carcinomas were included in Group 2; and lung, gastric, and hepatocellular carcinomas and melanoma in Group 1.
